Todays Report: The Equities Analysts Set Expectations for Immunomedics Inc.’s Q2 2017 Earnings (IMMU)

The Equities Analysts Set Expectations for Immunomedics Inc.’s Q2 2017 Earnings (IMMU)

Immunomedics Inc. (NASDAQ:IMMU) – Jefferies Group issued their Q2 2017 earnings per share (EPS) estimates for Immunomedics in a note issued to investors on Thursday. Jefferies Group analyst M. Andrews forecasts that the firm will post earnings per share of ($0.09) for the quarter. Jefferies Group has a “Buy” rating and a $5.50 price objective on the stock. Jefferies Group also issued estimates for Immunomedics’ Q3 2017 earnings at ($0.08) EPS, Q4 2017 earnings at ($0.07) EPS, FY2017 earnings at ($0.35) EPS, FY2018 earnings at ($0.17) EPS, FY2019 earnings at $0.08 EPS and FY2020 earnings at $0.23 EPS.

IMMU has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Immunomedics from a “hold” rating to a “strong sell” rating in a report on Monday, August 22nd. Wells Fargo & Co. downgraded shares of Immunomedics from an “outperform” rating to a “market perform” rating in a report on Tuesday, June 21st.

Shares of Immunomedics (NASDAQ:IMMU) opened at 2.58 on Monday. The company’s market cap is $247.33 million. Immunomedics has a 1-year low of $1.61 and a 1-year high of $5.44. The stock’s 50 day moving average is $2.98 and its 200 day moving average is $3.03.

10/10/equities-analysts-set-expectations-for-immunomedics-inc-s-q2-2017-earnings-immu.html

Immunomedics (NASDAQ:IMMU) last posted its quarterly earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by $0.06.

In other news, Director Mary E. Paetzold sold 15,000 shares of the stock in a transaction that occurred on Tuesday, August 23rd. The shares were sold at an average price of $2.98, for a total value of $44,700.00. Following the completion of the sale, the director now owns 82,474 shares of the company’s stock, valued at approximately $245,772.52. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Don C. Stark sold 9,900 shares of the stock in a transaction that occurred on Wednesday, August 24th. The shares were sold at an average price of $2.97, for a total transaction of $29,403.00. Following the completion of the sale, the director now directly owns 55,848 shares of the company’s stock, valued at approximately $165,868.56. The disclosure for this sale can be found here. 8.80% of the stock is currently owned by company insiders.

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Immunomedics by 1.9% in the second quarter. Vanguard Group Inc. now owns 3,677,769 shares of the biopharmaceutical company’s stock valued at $8,533,000 after buying an additional 69,890 shares during the period. Sabby Management LLC purchased a new stake in Immunomedics during the first quarter valued at $182,240,000. State Street Corp boosted its stake in Immunomedics by 63.3% in the second quarter. State Street Corp now owns 2,354,732 shares of the biopharmaceutical company’s stock valued at $5,463,000 after buying an additional 912,372 shares during the period. Opaleye Management Inc. boosted its stake in Immunomedics by 356.9% in the first quarter. Opaleye Management Inc. now owns 1,325,000 shares of the biopharmaceutical company’s stock valued at $3,313,000 after buying an additional 1,035,000 shares during the period. Finally, venBio Select Advisor LLC purchased a new stake in Immunomedics during the first quarter valued at $2,626,000. 53.79% of the stock is owned by institutional investors and hedge funds.

About Immunomedics

Related posts

Leave a Comment